Innovatus Capital Partners

Innovatus Capital Partners is an asset management company established in 2016 and based in New York City. The firm specializes in both real and financial assets, focusing on identifying distressed, disruptive, and growth opportunities. Innovatus provides asset class diversity and capital structure flexibility by acquiring assets to enhance, lease, sell, or allow to self-liquidate. Additionally, the firm engages in structuring royalty agreements, direct ownership stakes in companies, partnerships, and direct loans. Innovatus primarily serves clients in the life science and real estate sectors, emphasizing innovative investment strategies tailored to specific market conditions.

Bhagavatula CFA, Ravi

Partner

Claes Ekstrom

Investment Team and Managing Director - Head of Life Sciences

Holland, Jeffrey

Director

25 past transactions

Imperative Care

Series E in 2024
Imperative Care focuses on developing a portfolio of innovative solutions to address the vast and urgent unmet needs in stroke care. It focuses on medical technology designed to expedite and improve the effectiveness of treatment, giving patients a chance for optimal recovery.

Celcuity

Post in 2024
Celcuity Inc. is a clinical-stage biotechnology company based in Minneapolis, Minnesota, focused on advancing cancer treatment through innovative diagnostics. The company's CELsignia diagnostic platform utilizes living tumor cells to uncover specific cellular processes that drive cancer in individual patients. This approach enables the identification of new cancer sub-types that traditional molecular diagnostics may overlook, ultimately expanding therapeutic options. Celcuity is developing the CELsignia HSF test to diagnose two new sub-types of HER2-negative breast cancer and the CELsignia MP test for diagnosing 11 sub-types across various cancers, including breast, lung, colon, ovarian, kidney, and bladder. The company is also advancing its lead therapeutic candidate, gedatolisib, a pan-PI3K and mTOR inhibitor, currently being evaluated in a Phase 3 clinical trial for patients with advanced HR+/HER2- breast cancer.

Codexis

Post in 2024
Codexis, Inc. is an industrial biotechnology company that specializes in the engineering of enzymes for pharmaceutical and chemical production through biocatalysis. Established in 2002 and headquartered in Redwood City, California, Codexis develops and sells protein catalysts and intermediate chemical products, as well as offering protein catalyst screening and engineering services. The company employs its proprietary CodeEvolver technology platform, which facilitates enzyme optimization by introducing genetic mutations into microorganisms. This platform is utilized by over 50 pharmaceutical manufacturers globally to enhance their process development and manufacturing efficiency. Codexis generates most of its revenue through product sales and also licenses its technology to enable clients to engineer enzymes for their own applications. Its customer base spans various regions, including the United States, Europe, and parts of Asia.

JenaValve Technology

Series C in 2022
JenaValve Technology, Inc. is a medical device company specializing in the development and manufacturing of transcatheter aortic valve replacement (TAVR) systems designed for patients with severe aortic stenosis and aortic regurgitation. The company's flagship product, the Trilogy Heart Valve System, features a porcine pericardial trileaflet valve mounted on a self-expanding nitinol frame, which allows for both transapical and transfemoral implantation. This innovative system is particularly aimed at high-risk patients and has received CE Mark approval, as well as Breakthrough Device Designation from the U.S. Food and Drug Administration to expedite its review process in the United States. JenaValve operates from its headquarters in Irvine, California, with additional facilities in Munich, Germany, and Leeds, United Kingdom. The company aims to transform the treatment landscape for heart valve diseases through its advanced technologies.

MDxHealth

Post in 2022
MDxHealth is a molecular diagnostics company focused on developing and commercializing advanced tests for cancer assessment and personalized treatment. The company offers a range of products including ConfirmMDx, a prostate cancer testing solution that addresses false-negative biopsy concerns; SelectMDx, which helps guide repeat biopsies for prostate cancer; and AssureMDx, a noninvasive liquid biopsy test for bladder cancer that assists in decision-making for cystoscopy. Additionally, MDxHealth provides PredictMDx for Glioblastoma, a tissue methylation test that aids in treatment decisions for brain cancer. Founded in 2003 and headquartered in Irvine, California, MDxHealth operates additional offices in Herstal, Belgium, and Nijmegen, the Netherlands. The company generates revenue through clinical laboratory services and the out-licensing of its patented DNA methylation platform and biomarkers, serving markets in the United States and Europe.

Syapse

Venture Round in 2022
Syapse, Inc. is a company that develops a precision medicine software platform aimed at improving cancer care through the integration and analysis of diverse clinical, molecular, treatment, and outcomes data. By leveraging real-world evidence, Syapse enables healthcare organizations to collaborate effectively, providing comprehensive patient insights that inform clinical decisions. Its primary offering, the Syapse Learning Health Network, serves as a global data-sharing network that supports oncologists and life sciences collaborators with actionable insights derived from real-world data. Founded in 2008 and headquartered in San Francisco, California, with an additional office in Radnor, Pennsylvania, Syapse works to enhance precision medicine programs and drive impactful outcomes for cancer patients. The company has also established a strategic partnership with Pfizer to further its mission in the field of precision oncology.

Eiger BioPharmaceuticals

Post in 2022
Eiger BioPharmaceuticals is a privately held biotechnology company that develops a novel antiviral therapy for Hepatitis Delta, a life-threatening, Orphan Disease with high unmet medical need and no approved therapy. The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Its strategy is predicated upon time and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients.

Eiger BioPharmaceuticals

Post in 2022
Eiger BioPharmaceuticals is a privately held biotechnology company that develops a novel antiviral therapy for Hepatitis Delta, a life-threatening, Orphan Disease with high unmet medical need and no approved therapy. The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Its strategy is predicated upon time and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients.

DNAnexus

Series H in 2022
DNAnexus, Inc. is a provider of cloud-based genome informatics and data management tools aimed at enterprises engaged in genomic medicine. Founded in 2009 and headquartered in Mountain View, California, the company offers a platform that facilitates the analysis of raw sequencing data and integration with clinical and phenotypic data, promoting seamless collaboration among users. Key offerings include MOSAIC Microbiome, a platform for collaborative microbiome research; DNAnexus Apollo, which focuses on clinico-genomic data exploration; and DNAnexus Titan, a comprehensive data analysis solution. Additionally, DNAnexus Portals provide secure online workspaces for cross-disciplinary collaboration. The Clinico-Genomic Data Solution program addresses the need for disease-specific datasets by building networks with healthcare partners to enhance diagnosis and treatment pathways. DNAnexus serves a diverse client base, including biopharmaceutical companies, genome centers, and diagnostic test providers, and has established a strategic alliance with WuXi NextCODE Genomics. The company also maintains additional offices in San Francisco, London, and Prague.

Apollo Endosurgery

Post in 2021
Apollo Endosurgery, Inc. is a medical technology company based in Austin, Texas, that specializes in the design, development, and commercialization of devices for gastrointestinal therapeutic endoscopy. Founded in 2005, the company offers a range of innovative products aimed at reducing the need for invasive surgical procedures. Key offerings include the OverStitch and OverStitch Sx Endoscopic Suturing Systems, which allow physicians to place full-thickness sutures through a flexible endoscope, and the X-Tack Endoscopic HeliX Tacking System. Additionally, Apollo provides the Orbera Intragastric Balloon, which helps manage obesity by reducing stomach capacity. The company's solutions are designed to lower complication rates and overall healthcare costs, making them valuable tools for gastroenterologists and bariatric surgeons. Apollo Endosurgery distributes its products to medical service providers, hospitals, outpatient surgical centers, clinics, and physicians across the United States, Brazil, Australia, and various European countries.

Cala Health

Series D in 2021
Cala Health, Inc. is a bioelectronic medicine company based in Burlingame, California, founded in 2013. It specializes in developing wearable neuromodulation therapies aimed at treating chronic diseases. The company's flagship product, Cala Trio, is a non-invasive prescription therapy designed to provide transient relief from hand tremors in adults with essential tremor. By integrating advancements in neuroscience and technology, Cala Health focuses on delivering individualized peripheral nerve stimulation. In addition to its work on essential tremor, the company is also developing therapies for other neurological conditions, including Parkinson's disease, as well as applications in psychiatry, cardiology, and autoimmune disorders.

Geneoscopy

Series B in 2021
Geneoscopy, LLC, based in Saint Louis, Missouri, specializes in developing non-invasive diagnostic tests aimed at preventing, detecting, and guiding treatment for gastrointestinal diseases, particularly colorectal cancer. Founded in 2015, the company utilizes a proprietary platform that extracts stool-derived eukaryotic RNA (seRNA) to create a multi-target RNA biomarker panel. This innovative approach allows for the identification of colorectal cancer by capturing the effects of DNA mutations associated with the disease. Geneoscopy's technology not only enhances screening compliance but also facilitates the early detection of colorectal neoplasms, ultimately aiming to reduce morbidity and mortality linked to colorectal cancer. The company is also exploring additional applications of its technology for related gastrointestinal conditions.

Exagen

Post in 2021
Exagen Inc. is a diagnostics company focused on improving the care of patients with autoimmune diseases through the development and commercialization of innovative testing products under its AVISE brand. Utilizing its proprietary Cell-Bound Complement Activation Products technology, Exagen offers a range of tests aimed at the diagnosis, prognosis, and monitoring of complex autoimmune and autoimmune-related disorders, such as systemic lupus erythematosus and rheumatoid arthritis. Among its key products are AVISE CTD, which supports differential diagnosis for connective tissue diseases, and AVISE Lupus, which assesses complement system activation. The company's portfolio also includes AVISE APS for antiphospholipid syndrome, AVISE SLE Prognostic for risk assessment of complications, and tests for monitoring treatment efficacy in rheumatoid arthritis. Established in 2002 and headquartered in Vista, California, Exagen is dedicated to providing rheumatologists with timely and accurate diagnostic tools to enhance patient care.

Spacial

Seed Round in 2021
Spacial is a San Francisco based company building accessory dwelling units for homeowner's backyards. The ADUs are beautiful, spacious and airy, and we utilize offsite construction increase speed to installation and decrease costs to homeowners, while delivering a home built to the same standard as their primary residence.

Imperative Care

Series D in 2021
Imperative Care focuses on developing a portfolio of innovative solutions to address the vast and urgent unmet needs in stroke care. It focuses on medical technology designed to expedite and improve the effectiveness of treatment, giving patients a chance for optimal recovery.

Match Marketing Group

Acquisition in 2021
Match Marketing Group Inc. is a Canadian activation agency based in Mississauga, specializing in shopper marketing solutions designed to inspire consumer purchases through integrated experiences. Founded in 2011, the company offers a comprehensive range of services, including insights and strategy, digital marketing, experiential marketing, merchandising, and retail solutions. By focusing on the connected shopper, Match Marketing Group aims to enhance brand value and drive demand for its clients, which include notable brands such as adidas, GoGo Squeez, Malibu Rum, Lincoln Motor Company, and Ford. The agency's goal is to create seamless interactions that reflect modern shopping behaviors, facilitating effective consumer engagement both online and offline.

Personal Genome Diagnostics

Series C in 2021
Personal Genome Diagnostics, Inc. specializes in patient-specific cancer genome analysis using advanced digital characterization and monitoring technologies. Founded in 2010 and based in Baltimore, Maryland, the company offers a range of products and services aimed at improving cancer diagnosis and treatment. Their METDetect Assay detects MET gene amplifications in cancer patients' circulation, providing detailed reports on tumor-specific alterations. The LungSelect product identifies actionable genetic changes in plasma from non-small cell lung cancer patients, while PGDx elio plasma resolve is a diagnostic test that detects various genetic alterations in circulating cell-free DNA. Additionally, the company offers RNAcomplete, which allows for the extraction of total RNA and genomic DNA from single tissue samples, and CancerXOME, which analyzes the coding regions of numerous genes. Personal Genome Diagnostics collaborates with institutions like Mayo Clinic and has partnerships with KingMed Diagnostics to further enhance cancer genome research and diagnostics.

VSA Partners

Acquisition in 2021
VSA Partners, Inc. is a branding and marketing services firm founded in 1982 and headquartered in Chicago, Illinois, with additional offices in New York and San Francisco. The company, originally known as Vogele Stoik Associates, Inc., specializes in providing a range of services including strategy, digital systems, design, and marketing communications. VSA Partners aims to deliver interconnected branding solutions that enhance digital interactions for clients, facilitating engagement and facilitating audience connections. Their offerings encompass visual identity, corporate communication, retail design, and packaging, catering to businesses globally.

VICIS

Acquisition in 2020
VICIS is a Seattle-based company specializing in the development of advanced football helmet technology aimed at minimizing the risk of sports-related head injuries, particularly concussions. Founded in 2013, VICIS has created the ZERO1 helmet, which has been recognized for its innovative design and effectiveness, ranking first in the 2017 NFL/NFLPA Helmet Performance Testing. The ZERO1 is now used by NFL, NCAA, and select high school programs. By combining expertise in medicine and engineering, VICIS is dedicated to enhancing safety for athletes of all ages while improving their performance on the field.

Akoya Biosciences

Series D in 2019
Akoya Biosciences is a spatial biology company offering the most comprehensive, end-to-end solutions for high-parameter tissue analysis from discovery through clinical and translational research, enabling the development of more precise therapies for immuno-oncology and other drug development applications. The company has two industry-leading platforms that empower investigators and researchers to gain a deeper understanding of complex diseases such as cancer, and autoimmune or neurological disorders. The CODEX system is the only benchtop platform that can efficiently quantify more than 40 biomarkers and is ideally suited for biomarker discovery. The Phenoptics platform is the only end-to-end multiplexed immunofluorescence solution with the robustness and high throughput necessary for translational research and clinical trials.

ConforMIS

Post in 2019
ConforMIS is a medical technology company based in the United States that specializes in joint replacement implants and instruments. Utilizing its proprietary iFit® Image-to-Implant® technology platform, ConforMIS develops and manufactures personalized implants that are uniquely sized and shaped to match each patient's anatomy. The company's offerings include a wide range of sterile knee and hip implants, such as partial and total knee replacements, along with single-use surgical instruments. ConforMIS's iFit technology encompasses design, printing, and just-in-time delivery, allowing for customized solutions that enhance patient outcomes. The company primarily generates revenue through sales to hospitals and ambulatory surgical centers, positioning itself within the knee replacement market.

ConforMIS

Post in 2019
ConforMIS is a medical technology company based in the United States that specializes in joint replacement implants and instruments. Utilizing its proprietary iFit® Image-to-Implant® technology platform, ConforMIS develops and manufactures personalized implants that are uniquely sized and shaped to match each patient's anatomy. The company's offerings include a wide range of sterile knee and hip implants, such as partial and total knee replacements, along with single-use surgical instruments. ConforMIS's iFit technology encompasses design, printing, and just-in-time delivery, allowing for customized solutions that enhance patient outcomes. The company primarily generates revenue through sales to hospitals and ambulatory surgical centers, positioning itself within the knee replacement market.

DNAnexus

Series F in 2019
DNAnexus, Inc. is a provider of cloud-based genome informatics and data management tools aimed at enterprises engaged in genomic medicine. Founded in 2009 and headquartered in Mountain View, California, the company offers a platform that facilitates the analysis of raw sequencing data and integration with clinical and phenotypic data, promoting seamless collaboration among users. Key offerings include MOSAIC Microbiome, a platform for collaborative microbiome research; DNAnexus Apollo, which focuses on clinico-genomic data exploration; and DNAnexus Titan, a comprehensive data analysis solution. Additionally, DNAnexus Portals provide secure online workspaces for cross-disciplinary collaboration. The Clinico-Genomic Data Solution program addresses the need for disease-specific datasets by building networks with healthcare partners to enhance diagnosis and treatment pathways. DNAnexus serves a diverse client base, including biopharmaceutical companies, genome centers, and diagnostic test providers, and has established a strategic alliance with WuXi NextCODE Genomics. The company also maintains additional offices in San Francisco, London, and Prague.

Personal Genome Diagnostics

Private Equity Round in 2018
Personal Genome Diagnostics, Inc. specializes in patient-specific cancer genome analysis using advanced digital characterization and monitoring technologies. Founded in 2010 and based in Baltimore, Maryland, the company offers a range of products and services aimed at improving cancer diagnosis and treatment. Their METDetect Assay detects MET gene amplifications in cancer patients' circulation, providing detailed reports on tumor-specific alterations. The LungSelect product identifies actionable genetic changes in plasma from non-small cell lung cancer patients, while PGDx elio plasma resolve is a diagnostic test that detects various genetic alterations in circulating cell-free DNA. Additionally, the company offers RNAcomplete, which allows for the extraction of total RNA and genomic DNA from single tissue samples, and CancerXOME, which analyzes the coding regions of numerous genes. Personal Genome Diagnostics collaborates with institutions like Mayo Clinic and has partnerships with KingMed Diagnostics to further enhance cancer genome research and diagnostics.

Exagen

Debt Financing in 2017
Exagen Inc. is a diagnostics company focused on improving the care of patients with autoimmune diseases through the development and commercialization of innovative testing products under its AVISE brand. Utilizing its proprietary Cell-Bound Complement Activation Products technology, Exagen offers a range of tests aimed at the diagnosis, prognosis, and monitoring of complex autoimmune and autoimmune-related disorders, such as systemic lupus erythematosus and rheumatoid arthritis. Among its key products are AVISE CTD, which supports differential diagnosis for connective tissue diseases, and AVISE Lupus, which assesses complement system activation. The company's portfolio also includes AVISE APS for antiphospholipid syndrome, AVISE SLE Prognostic for risk assessment of complications, and tests for monitoring treatment efficacy in rheumatoid arthritis. Established in 2002 and headquartered in Vista, California, Exagen is dedicated to providing rheumatologists with timely and accurate diagnostic tools to enhance patient care.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.